Clinical Trial Update: X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 study update of X-396 (ensartinib) in ALK-positive non-small cell lung cancer patients with brain metastases. The trial status is active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• X-396 (Ensartinib) (ensartinib)

Snippet

Sponsor: Fudan University | Conditions: Nonsmall Cell Lung Cancer, Brain Metastases | Phase 2 | Status: ACTIVE_NOT_RECRUITING